Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019
Vivoryon Therapeutics Reports Third Quarter 2019
HALLE (SAALE), Germany, 27 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today that management of Vivoryon Therapeutics will attend the CTAD (Clinical Trials on Alzheimer’s Disease) conference 2019 held from December 4-7, 2019, in San Diego, Ca., USA.
Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, will be in attendance and present for discussion a poster on the design and methods of the proposed phase 2 PQ912 clinical trial funded by grant R01AG061146 from the National Institute on Aging. The poster presentation will take place on December 5, 2019 at 10:00am PST in the Indigo Foyer.
Poster 36: “A seamless phase 2a-2b randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of PQ912 in patients with early Alzheimer’s disease: design and methods.”
This poster will be presented by Howard Feldman, MD, FRCP(C), professor of neurosciences and director of the Alzheimer’s Disease Cooperative Study (ADCS) at University of California San Diego.
###
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com
Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 176 2103 7191
Email: Trophic@vivoryon.com
MC Services AG
Anne Hennecke / Susanne Kutter
Tel: +49 (0) 211 529 252 27
Email: vivoryon@mc-services.eu
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.